immunology 2017™ Meeting (2017/05/12-16))Abstracts 
The Journal of JImmunology May 1, 2017, 198 (1 Supplement)

http://www.jimmunol.org/content/198/1_Supplement
[
注] リスト書式:通し番号;タイトル;URL;タイトルにCRISPRが含まれていな場合はアブストラクトの該当部分を付加

1.       The Nrf2 activators tBHQ and CDDO-Im have both Nrf2-dependent and – independent effects on human Jurkat T cell activation, as determined by CRISPR-Cas9 gene editing

http://www.jimmunol.org/content/198/1_Supplement/124.4

2.       Dissecting T follicular helper cell development in vivo using CRISPR

http://www.jimmunol.org/content/198/1_Supplement/152.2

3.       KEAP1 gene editing using CRISPR/Cas9 for therapeutic NRF2 activation in human T cells

http://www.jimmunol.org/content/198/1_Supplement/82.29

4.       Investigating the molecular mechanism of CRISPR-Cas adaptation of Streptococcus thermophilus

http://www.jimmunol.org/content/198/1_Supplement/67.11

5.       Optimization of Gene Editing in Human Primary T Cells with Neon® Transfection System - “For CRISPR/Cas9 gene editing, more than 30% knock-in efficiency was observed while cleavage efficiency at HPRT locus can be reached more than 70%.”

http://www.jimmunol.org/content/198/1_Supplement/73.24

6.       Knockout validation of antibodies to Ki67: a marker for cellular proliferation - “and the use of their KO cell lines generated using CRISPR/Cas9 technology

http://www.jimmunol.org/content/198/1_Supplement/213.10

7.       Immunology Antibody Validation: PTEN a target case in the use of human KO cell lines for antibody validation - “and the use of their KO cell lines generated using CRISPR/Cas9 technology

http://www.jimmunol.org/content/198/1_Supplement/213.15

8.       Hyperactivation of PI3 kinase causes defects in human B-cell development and differentiation - “we generated a mouse model using CRISPR/Cas9 to introduce the common disease-causing mutation (E1021K) into Pik3cd.

http://www.jimmunol.org/content/198/1_Supplement/59.1

9.       The role of MHC class II polymorphisms for DM-mediated peptide editing and autoimmunity – “we introduced selected mutations in the genome of the NOD mouse by CRISPR/Cas9 genomic editing.
http://www.jimmunol.org/content/198/1_Supplement/156.24